Revance Therapeutics, Inc.

RVNC

US7613301099

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
3.4 ^USD	+3.34%		-10.05%	-61.32%

Apr. 26	AbbVie raises annual profit forecast on strong Skyrizi sales	RE
Apr. 12	Revance Therapeutics, Inc. to Present New DAXXIFY Data at the American Academy of Neurology 2024 Annual Meeting	CI

Revance Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023

February 28, 2024 at 04:07 pm EST

Revance Therapeutics, Inc. reported earnings results for the fourth quarter and full year ended December 31, 2023. For the fourth quarter, the company reported revenue was USD 69.8 million compared to USD 49.92 million a year ago. Net loss was USD 55.7 million compared to USD 145.95 million a year ago. Basic loss per share from continuing operations was USD 0.62 compared to USD 1.82 a year ago.
For the full year, revenue was USD 234.04 million compared to USD 132.57 million a year ago. Net loss was USD 323.99 million compared to USD 356.42 million a year ago. Basic loss per share from continuing operations was USD 3.83 compared to USD 4.9 a year ago.

Latest news about Revance Therapeutics, Inc.

AbbVie raises annual profit forecast on strong Skyrizi sales	Apr. 26	RE
Revance Therapeutics, Inc. to Present New DAXXIFY Data at the American Academy of Neurology 2024 Annual Meeting	Apr. 12	CI
Transcript : Revance Therapeutics, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-12-2024 09:30 AM	Mar. 12
North American Morning Briefing: Stock Futures Fall With Investor Focus on Inflation Data	Mar. 11	DJ
Revance Therapeutics Prices $100 Million Public Offering	Mar. 04	MT
Goldman Sachs Adjusts Price Target on Revance Therapeutics to $9 From $8, Maintains Neutral Rating	Mar. 01	MT
Needham Cuts Price Target on Revance Therapeutics to $18 From $20, Maintains Buy Rating	Feb. 29	MT
Piper Sandler Cuts Price Target on Revance Therapeutics to $20 From $42, Maintains Overweight Rating	Feb. 29	MT
Transcript : Revance Therapeutics, Inc., Q4 2023 Earnings Call, Feb 28, 2024	Feb. 28
Earnings Flash (RVNC) REVANCE THERAPEUTICS Posts Q4 Revenue $69.8M	Feb. 28	MT
Revance Therapeutics, Inc. Provides Revenue Guidance for the Year 2024	Feb. 28	CI
Revance Therapeutics, Inc. Announces Executive Changes	Feb. 28	CI
Revance Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Feb. 28	CI
Revance Therapeutics Gets Permanent J-Code for Daxxify	Feb. 02	DJ
Revance Therapeutics, Inc. Receives Permanent J-Code for DAXXIFY and Announces Publication of Daxify Pivotal Study (ASPEN-1) Results in Neurology	Feb. 02	CI
AbbVie profit beats estimates as Humira, Botox sales weather hit from rivals	Feb. 02	RE
North American Morning Briefing : Microsoft Kicks -2-	Jan. 30	DJ
Mizuho Securities Downgrades Revance Therapeutics to Neutral From Buy, Lowers Price Target to $9 From $16	Jan. 29	MT
Needham Cuts Price Target on Revance Therapeutics to $20 From $25, Maintains Buy Rating	Jan. 09	MT
Goldman Sachs Downgrades Revance Therapeutics to Neutral From Buy, Cuts Price Target to $8 From $30	Jan. 09	MT
US Consumer Advocacy Group Seeks to Strengthen Warnings on Botox Labeling	Dec. 12	MT
US Consumer group seeks stronger warnings on Botox, similar treatments	Dec. 12	RE
Mizuho Adjusts Revance Therapeutics' Price Target to $16 From $35, Maintains Buy Rating	Nov. 22	MT
Piper Sandler Adjusts Revance Therapeutics' Price Target to $42 From $44, Maintains Overweight Rating	Nov. 09	MT
Needham Adjusts Revance Therapeutics Price Target to $25 From $35, Maintains Buy Rating	Nov. 09	MT

Chart Revance Therapeutics, Inc.

Duration

Period

More charts

Company Profile

Revance Therapeutics, Inc. is a biotechnology company focused on developing and commercializing aesthetic and therapeutic offerings. The Company's portfolio includes DAXXIFY (DaxibotulinumtoxinA-lanm) for injection and the RHA Collection of dermal fillers in the United States. It has also partnered with Viatris to develop a biosimilar to onabotulinumtoxinA for injection and Fosun to commercialize DAXXIFY in China. Its product/product candidate includes DAXXIFY for glabellar lines indication; DAXXIFY for cervical dystonia indication; RHA Redensity for perioral rhytids indication; RHA 2/ RHA 3/ RHA 4 for facial wrinkles and folds (such as nasolabial folds) indication; DAXXIFY for forehead lines, lateral canthal lines, upper facial lines indication; DAXXIFY for upper limb spasticity indication, and onabotulinumtoxinA biosimilar. The Company has exclusive right to import, market, promote, sell and distribute Teoxane's line of Resilient Hyaluronic Acid dermal fillers.

Sector

Pharmaceuticals

Calendar

2024-05-01 - Annual General Meeting

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Revance Therapeutics, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

D+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

3.4 USD

Average target price

16.33 USD

Spread / Average Target

+380.39%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Biopharmaceuticals

	1st Jan change	Capi.
REVANCE THERAPEUTICS, INC.	-61.32%	354M
CSL LIMITED	-4.66%	86.13B
SAMSUNG BIOLOGICS CO.,LTD.	+1.32%	39.82B
BIOGEN INC.	-19.27%	30.42B
UCB	+57.86%	25.23B
BIOMARIN PHARMACEUTICAL INC.	-16.09%	15.35B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-9.14%	11.95B
INCYTE CORPORATION	-17.69%	11.6B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-43.00%	11.51B
SWEDISH ORPHAN BIOVITRUM AB	+5.24%	8.71B

Biopharmaceuticals